Management of Rhabdomyolysis in Primary Angiitis
In patients with rhabdomyolysis secondary to primary angiitis (such as polyarteritis nodosa), treat the underlying vasculitis aggressively with cyclophosphamide and glucocorticoids while simultaneously providing aggressive intravenous fluid resuscitation for the rhabdomyolysis itself.
Treating the Underlying Vasculitis
The primary driver of rhabdomyolysis in this context is ischemic muscle necrosis from vasculitic involvement of medium-sized vessels supplying skeletal muscle. For severe manifestations of polyarteritis nodosa (PAN)—which includes tissue ischemia and muscle involvement—the 2021 ACR/Vasculitis Foundation guidelines strongly recommend cyclophosphamide combined with glucocorticoids for remission induction 1. The 2009 EULAR guidelines similarly recommend this combination for generalized primary small and medium vessel vasculitis 2.
The case report by 3 demonstrates this approach: a 71-year-old man with PAN presenting with rhabdomyolysis (CK 13,435 IU/L) and muscle weakness was successfully treated with methylprednisolone pulse therapy followed by oral prednisolone 50 mg/day plus monthly intravenous cyclophosphamide 500 mg, achieving sustained remission. The muscle biopsy showed fibrinoid necrosis of medium-sized vessels with muscle necrosis localized to arterial distribution patterns, confirming ischemic etiology.
Treatment Algorithm for the Vasculitis Component:
- High-dose glucocorticoids: Methylprednisolone pulse therapy (typically 500-1000 mg IV daily for 3 days) followed by oral prednisolone 1 mg/kg/day 1, 2
- Cyclophosphamide: Either oral (2 mg/kg/day) or intravenous (500-750 mg/m² monthly) 2
- Duration: Continue cyclophosphamide for 3-6 months for remission induction, then transition to maintenance therapy with azathioprine, methotrexate, or leflunomide 2
Managing the Rhabdomyolysis
While treating the underlying vasculitis, aggressive intravenous fluid resuscitation is the cornerstone of rhabdomyolysis management 4. The 2022 EAST practice management guideline conditionally recommends aggressive IVFR to decrease acute renal failure and need for dialysis 4.
Fluid Resuscitation Protocol:
- Volume: 3 L/m²/day of crystalloid solution 5
- Goal: Maintain urine output >200-300 mL/hour initially
- Monitor: Serial creatine kinase, creatinine, electrolytes, and urine output
What NOT to Do:
The 2022 EAST guideline conditionally recommends AGAINST routine use of bicarbonate or mannitol 4. Despite historical practice, these agents have not demonstrated benefit in preventing acute renal failure in rhabdomyolysis.
Monitoring and Complications
Key laboratory markers to follow:
- Creatine kinase: Typically peaks within 24-48 hours and should decline with treatment
- Serum creatinine: Normal admission creatinine has 95% specificity for ruling out AKI development 6
- Electrolytes: Watch for hyperkalemia, hyperphosphatemia, and hypocalcemia
- Myoglobin: Can be monitored but CK is more practical
Risk Stratification:
Patients with elevated serum creatinine above normal reference range at admission are at high risk for AKI 6. In the vasculitis context, this is particularly important as renal involvement may be multifactorial (vasculitic renal disease plus myoglobin-induced injury).
Critical Pitfalls to Avoid:
- Don't delay immunosuppression: Rhabdomyolysis in PAN represents severe, organ-threatening disease requiring immediate aggressive treatment of the vasculitis 1
- Don't use bicarbonate or mannitol routinely: No proven benefit and may cause harm 4
- Don't underestimate fluid needs: These patients require substantially more aggressive hydration than typical rhabdomyolysis cases
- Don't miss compartment syndrome: Examine for this complication, though rare in vasculitic rhabdomyolysis 7
Expected Clinical Course:
With appropriate dual therapy (immunosuppression + fluid resuscitation), CK levels typically decline over days to weeks. The case report 3 showed sustained remission at 2 months. However, some patients may have prolonged elevation of CK (1-3 months) even with appropriate treatment 8, so don't prematurely escalate therapy if clinical improvement is occurring.